The global demand for AstraZeneca’s Vaxzevria coronavirus vaccine has decreased due to the availability of numerous new vaccines. Despite being widely used globally with over 3 billion doses supplied since its first administration in the UK on January 4, 2021, the company has not generated revenue from the vaccine since April 2023.
The decline in demand for Vaxzevria is attributed to the surplus of updated Covid-19 vaccines that have been developed. As a result, AstraZeneca has made the decision to stop manufacturing and supplying the vaccine. The company has initiated the withdrawal of marketing authorizations for Vaxzevria within Europe, as announced by the European Medicines Agency.
AstraZeneca expressed pride in the role that Vaxzevria played in combating the global pandemic, despite its withdrawal from commercial demand. The situation is still developing and updates will be provided as needed.
